Evidence map›Paper›PMID 31467641›Full record

ArticleOxidative medicine and cellular longevity2019

Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma.

Esther Hernández-SanMiguel, Ricardo Gargini, Teresa Cejalvo, Berta Segura-Collar, Paula Núñez-Hervada, Rafael Hortigüela, Juan M Sepúlveda-Sánchez, Aurelio Hernández-Laín, Angel Pérez-Núñez, Eduardo Sanz and 1 more

Abstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. In vivo generation of CAR macrophages via the enucleated mesenchymal stem cell delivery system for glioblastoma therapy.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. NKG2C/Journal for immunotherapy of cancer · 2024
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Macrophages/Microglia in the Glioblastoma Tumor Microenvironment.International journal of molecular sciences · 2021
    Review
  9. Article
  10. Ocoxin as a complement to first line treatments in cancer.International journal of medical sciences · 2021
    Review
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Esther Hernández-SanMiguelNeurooncology Unit, Instituto de Salud Carlos III-UFIEC, Madrid, Spain.
Ricardo GarginiCentro de Biología Molecular, CSIC, Madrid, Spain.ORCID https://orcid.org/0000-0003-4032-0095
Teresa CejalvoUnidad Multidisciplinar de Neurooncología, Hospital Universitario 12 de Octubre, Madrid, Spain.
Berta Segura-CollarNeurooncology Unit, Instituto de Salud Carlos III-UFIEC, Madrid, Spain.
Paula Núñez-HervadaNeurooncology Unit, Instituto de Salud Carlos III-UFIEC, Madrid, Spain.
Rafael HortigüelaNeurooncology Unit, Instituto de Salud Carlos III-UFIEC, Madrid, Spain.
Juan M Sepúlveda-SánchezUnidad Multidisciplinar de Neurooncología, Hospital Universitario 12 de Octubre, Madrid, Spain.
Aurelio Hernández-LaínUnidad Multidisciplinar de Neurooncología, Hospital Universitario 12 de Octubre, Madrid, Spain.
Angel Pérez-NúñezUnidad Multidisciplinar de Neurooncología, Hospital Universitario 12 de Octubre, Madrid, Spain.
Eduardo SanzCatalysis S.L., Madrid, Spain.
Pilar Sánchez-GómezNeurooncology Unit, Instituto de Salud Carlos III-UFIEC, Madrid, Spain.ORCID https://orcid.org/0000-0002-0709-4973

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common and devastating primary brain tumor. The presence of cancer stem cells (CSCs) has been linked to their therapy resistance. Molecular and cellular components of the tumor microenvironment also play a fundamental role in the aggressiveness of these tumors. In particular, high levels of hypoxia and reactive oxygen species participate in several aspects of GBM biology. Moreover, GBM contains a large number of macrophages, which normally behave as immunosuppressive tumor-supportive cells. In fact, the presence of both, hypoxia and M2-like macrophages, correlates with malignancy and poor prognosis in gliomas. Antioxidant agents, as nutritional supplements, might have antitumor activity. Ocoxin® oral solution (OOS), in particular, has anti-inflammatory and antioxidant properties, as well as antitumor properties in several neoplasia, without known side effects. Here, we describe how OOS affects stem cell properties in certain GBMs, slowing down their tumor growth. In parallel, OOS has a direct effect on macrophage polarization

Indexed as

AnimalsAscorbic AcidFolic AcidGlioblastomaHumansMacrophagesMiceMice, NudeNeoplastic Stem CellsPantothenic AcidPlant ExtractsVitamin B 12Vitamin B 6Zinc SulfateAscorbic AcidFolic AcidOcoxinPantothenic AcidPlant ExtractsVitamin B 12Vitamin B 6Zinc Sulfate

Identifiers

PMID31467641
PMCPMC6701394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.